CRISPR Technology Global Market Report 2025

CRISPR technology is a groundbreaking gene-editing tool that allows for precise modifications of DNA in living organisms. It is utilized to alter genes for a range of applications, including disease treatment, enhancements in agriculture, and biological research.

The primary product categories in CRISPR technology include design tools, plasmids and vectors, CAS9 and G-RNA components, and delivery systems. CRISPR-Cas9 is an innovative tool allowing scientists to edit specific genome sections by adding, removing, or altering DNA sequences. Applications encompass genome editing, genetic engineering, agricultural biotechnology, among others, and find utility across various sectors including industrial biotech, biological and agricultural research, therapeutics, and drug discovery.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The CRISPR technology market research report is one of a series of new reports from The Business Research Company that provides CRISPR technology market statistics, including CRISPR technology industry global market size, regional shares, competitors with a CRISPR technology market share, detailed CRISPR technology market segments, market trends and opportunities, and any further data you may need to thrive in the CRISPR technology industry. This CRISPR technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The crispr technology market size has grown exponentially in recent years. It will grow from $2.05 billion in 2024 to $2.53 billion in 2025 at a compound annual growth rate (CAGR) of 23.4%. The growth in the historic period can be attributed to a rise in funding and an increase in pharmaceutical R&D expenditure.

The crispr technology market size is expected to see exponential growth in the next few years. It will grow to $5.71 billion in 2029 at a compound annual growth rate (CAGR) of 22.6%. The growth in the forecast period can be attributed to rising demand for gene therapeutics, technological advancements in the fields of genome editing, growing demand for the discovery of drugs, increasing demand for CRISPR in diagnostics, rising demand for CRISPR technologies in agriculture applications, and rising adoption of CRISPR technologies. Major trends in the forecast period include developing innovative next-generation technology, developing improved CRISPR technologies for better results in new drug developments, using AI to improve the efficiency and accuracy of gene editing with CRISPR, investing in new approaches such as IDMseq to increase accuracy, and establishing collaborations with companies.

The forecast of 22.6% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. market by increasing the cost of Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) gene-editing tools and reagents sourced from South Korea and Canada, thereby slowing biomedical research progress and elevating biotech development costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The adoption of CRISPR technology as a diagnostic tool is poised to elevate the market's trajectory. Notably, the Sherlock CRISPR SARS-CoV-2 kit stands out as the inaugural diagnostic kit employing CRISPR technology for infectious diseases, particularly COVID-19. In February 2021, the FDA granted emergency use authorization to Sherlock BioSciences Inc.'s CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test. This kit exhibits high specificity and sensitivity, targeting RNA or DNA sequences of the SARS-CoV-2 virus with precision from various specimens. Its reliability in avoiding false negatives or positives positions CRISPR technology as a pivotal player in infectious disease diagnosis, fostering a surge in demand for CRISPR products and services.

Leading companies in the CRISPR technology market are pursuing a strategic partnership approach to develop treatments for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Strategic partnerships involve companies utilizing each other's strengths and resources to achieve mutual advantages and success. For example, in November 2023, Vertex, a UK-based call center company, formed a partnership with CRISPR Therapeutics, a biotechnology firm based in Switzerland. This collaboration aims to create innovative solutions and has led to the launch of the CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM). This therapy, known as CASGEVY (exagamglogene autotemcel), employs CRISPR/Cas9 technology to modify genes in hematopoietic stem cells, facilitating the production of functional hemoglobin. This advancement has the potential to significantly reduce or eliminate the painful vaso-occlusive crises linked to sickle cell disease and lessen the necessity for blood transfusions in patients with transfusion-dependent beta-thalassemia.

Major companies in the CRISPR technology market are concentrating on creating advanced gene editing tools to improve precision in genomic modifications for use in medicine, agriculture, and biotechnology. Gene-editing tools are technologies that enable precise alterations to an organism's DNA, facilitating the addition, deletion, or modification of genetic material. Tools like CRISPR-Cas9 allow for targeted changes to genes, pushing forward research in genetics, medicine, and biotechnology. For example, in May 2024, Profluent Bio Inc., an Ireland-based AI-driven protein design firm, introduced OpenCRISPR-1 to Edit the Human Genome. This tool provides significant advantages in gene editing by achieving a 95% reduction in off-target effects, enhancing the accuracy of genetic modifications compared to conventional CRISPR systems. Its open-source nature also enables researchers globally to tailor and refine the tool for various uses, encouraging ethical applications and speeding up the creation of new therapies for genetic disorders.

In February 2023, Sherlock Biosciences, a US-based health company dedicated to developing diagnostic tools that make health information more accessible, accurate, and affordable, acquired Sense Biodetection for an undisclosed sum. This acquisition is aimed at speeding up the development of user-friendly, CRISPR-based diagnostic tools that provide consumers with accurate health testing. Sense Biodetection Limited is a UK-based molecular diagnostics firm specializing in rapid, point-of-care diagnostic solutions.

Major companies operating in the CRISPR technology market include Crispr Therapeutics, Thermo Fisher Scientific, Intellia Therapeutics, Horizon Discovery, Synthego Corporation, Integrated Dna Technology (Danaher), Editas Medicine, GenScript, Agilent Technologies, New England Biolabs, CSIR-Institute of Genomics & Integrative Biology (IGIB), Strand Life Sciences Pvt. Ltd., Bio Palette Co. Ltd., CSL Limited, C4U Co. Ltd., BGI Group, Churchi Genome Engineering and Therapeutic Research Center., Beam Therapeutics Inc., Eurofins Genomics India, Setsurotech Co. Ltd., Merck Japan, Institut Pasteur, CureVac, Cellectis, BiovelocITA S.r.l., Evotec A.G., SNIPR Biome, Oxford Genetics, ERS Genomics, Alia Therapeutics, Solvo, BioTalentum, Rosneft, BIOCAD, BioVendor, Research & Diagnostic Products, Contipro, Lonza Biotec, Sotio, Selvita, BioVentures Institute Ltd, Sigma-Aldrich, Poseida Therapeutics, NanoCellect Biomedical, Sherlock Biosciences, Repare Therapeutics, Inscripta Inc., Santa Cruz Biotechnology, Caribou Biosciences Inc., Egenesis Inc., Homology Medicines, System Biosciences, Takara Bio USA Inc., Inari Agriculture Inc., Precision BioSciences, Cell Microsystems Inc., GeneCopoeia Inc., Horizon Discovery Group, Merck KGaA, Origene Technologies Inc., Pluristem Therapeutics Inc.

North America was the largest region in the CRISPR technology market in 2024. Western Europe was the second largest region in the global CRISPR technology market. The regions covered in the CRISPR technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the CRISPR technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The CRISPR technology market includes revenue earned by CRISPR Screening Libraries, CRISPR Positive Controls, CRISPR Negative Controls, and Gene-specific Knockout Kits. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CRISPR Technology Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on crispr technology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for crispr technology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The crispr technology market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Design Tools, Plasmid And Vector, Cas9 And G-RNA, Delivery System Products
• 2) By Application: Biomedical, Agriculture, Diagnostics, Other Applications
• 3) By End-User: Academic Research Organizations, Biopharmaceutical Companies, Agricultural Biotechnology Companies, Contract Research Organizations (CROs)
• Subsegments:
• 1) By Design Tools: CRISPR Design Software; sgRNA Design Tools; Bioinformatics Platforms
• 2) By Plasmid and Vector: Plasmid Vectors; Viral Vectors; Bacterial Vectors
• 3) By Cas9 and gRNA: Cas9 Proteins; Guide RNA (gRNA) Products; Cas9 Complexes
• 4) By Delivery System Products: Electroporation Systems; Lipid-Based Delivery Systems; Viral Delivery Systems; Nanoparticle-Based Delivery Systems
• Companies Mentioned: Crispr Therapeutics; Thermo Fisher Scientific; Intellia Therapeutics; Horizon Discovery; Synthego Corporation; Integrated Dna Technology (Danaher); Editas Medicine; GenScript; Agilent Technologies; New England Biolabs; CSIR-Institute of Genomics & Integrative Biology (IGIB); Strand Life Sciences Pvt. Ltd.; Bio Palette Co. Ltd.; CSL Limited; C4U Co. Ltd.; BGI Group; Churchi Genome Engineering and Therapeutic Research Center.; Beam Therapeutics Inc.; Eurofins Genomics India; Setsurotech Co. Ltd.; Merck Japan; Institut Pasteur; CureVac; Cellectis; BiovelocITA S.r.l.; Evotec A.G.; SNIPR Biome; Oxford Genetics; ERS Genomics; Alia Therapeutics; Solvo; BioTalentum; Rosneft; BIOCAD; BioVendor; Research & Diagnostic Products; Contipro; Lonza Biotec; Sotio; Selvita; BioVentures Institute Ltd; Sigma-Aldrich; Poseida Therapeutics; NanoCellect Biomedical; Sherlock Biosciences; Repare Therapeutics; Inscripta Inc.; Santa Cruz Biotechnology; Caribou Biosciences Inc.; Egenesis Inc.; Homology Medicines; System Biosciences; Takara Bio USA Inc.; Inari Agriculture Inc.; Precision BioSciences; Cell Microsystems Inc.; GeneCopoeia Inc.; Horizon Discovery Group; Merck KGaA; Origene Technologies Inc.; Pluristem Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.